Absci Corporation (ABSI)

Overview

Absci Corporation is positioned at the forefront of the pharmaceutical industry as a pioneering data-first generative artificial intelligence (AI) drug creation company based in the United States. Founded in 2011 and headquartered in Vancouver, Washington, Absci sets itself apart by integrating AI with scalable wet laboratory technologies. This unique fusion is geared towards the expeditious creation of biologic drugs aimed at addressing patients' needs across various conditions. The company’s innovative approach aims to enhance the traditional biologic drug discovery process. By leveraging AI, it seeks to concurrently optimize several drug attributes critical to development and therapeutic efficacy. Absci has also established a collaborative effort with the Memorial Sloan Kettering Cancer Center, focusing on the discovery of novel therapeutics through the use of generative AI, underscoring its commitment to advancing medical research and treatment.

Products and Services

• Integrated Drug Creation Platform

This flagship offering by Absci harnesses the power of generative AI in conjunction with scalable wet lab technologies to revolutionize the biologic drug discovery process. The platform is meticulously designed to optimize multiple drug characteristics simultaneously, significantly improving the efficiency and efficacy of developing therapeutic biologics. This holistic approach not only accelerates the pipeline of drug discovery but also ensures that the drugs developed are of high therapeutic potential, catering to the nuanced needs of patients.

• Collaborative Research in Therapeutic Discovery

The partnership with Memorial Sloan Kettering Cancer Center showcases Absci's dedication to leveraging its generative AI and wet lab expertise in the quest for groundbreaking therapeutics. By working closely with a leading cancer research institution, Absci not only extends its scientific prowess into oncology but also enriches its drug discovery platform with valuable insights into cutting-edge cancer treatments. This collaboration represents a strategic effort to fuse AI’s predictive capabilities with clinical insights, aiming to uncover novel therapeutic pathways and options for patients.